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 Aims of the study:-
1. To determine the incidence of clinical and subclinical 
hypothyroidism in patients undergoing  radiation therapy for 
head and neck carcinomas 
2. To determine the factors influencing the occurrence of 
hypothyroidism 
3. To evaluate impact on quality of life  
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Introduction- 
 Head and neck malignancies are one of the most common malignancies in world and 
India. A vast majority of patients of head and neck malignancies are treated with radiotherapy. 
There has been evidence that such radiation to the neck may result in post radiotherapy 
hypothyroidism. The incidence of post radiotherapy hypothyroidism in as reported in various 
literature varies from as low as 6% (1) to as high as 68% (2) However, there is considerable 
debate regarding the incidence, influencing factors responsible, relationship with dose and time 
of development of the same. The available data for Indian patients, as found by Aich et al shows 
an incidence of 0.57% at 6 weeks and 21.8% at two years (3).   Biochemical investigations are 
available for determination of hypothyroidism and supplementation with exogenous thyroxin is 
possible. Hypothyroidism manifests as fatigue, poor appetite, and temper fluctuation, leading to 
inability to meet social and familial roles. They also do effect on the professional and economic 
productivity of the patient and the family. This adds to the financial strain that results from the 
cost of care and loss of work days during the treatment period. Hypothyroidism also results in 
long term complications with respect to cardiac and general morbidity. Such morbidity in cancer 
survivors can be of immense physical, emotional, social and economic problems. Thus early 
detection and treatment of post radiotherapy hypothyroidism can result in avoidance of such 
complications and help in improving the quality of life. Most of the guidelines have been 
developed on basis of the western data. The applicability of the same, to Indian population, is not 
well defined, especially, in view of heterogeneity of data, originating from different population 
of the world. This not only includes the incidence but also time of occurrence of hypothyroidism 
post radiotherapy.  This study is an endeavor to determine the incidence, associated factors in 
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development of hypothyroidism including the temporal association of the incidence with respect 
to the population from the Indian subcontinent.  
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Literature review 
Carcinoma of the head & neck region is the commonest malignancy among Indian males, 
as per ICMR reports (4).  
Sites of head and neck malignancies: 
Carcinomas of the head and neck region, generally refers to the malignancies of the 
following sites:- 
1. Nasopharynx [ICD-O-3:C 11] 
2. Nasal cavity and middle ear [ICD-O-3:C30] 
3. Accessory sinuses [ICD-O-3:C31] 
4. Lip and Oral cavity [ICD-O-3:C00-08] 
5. Tonsils and Oropharynx[ICD-O-3:C09-10] 
6. Piryform sinus and Hypopharynx [ICD-O-3:C12-13] 
7. Other and ill-defined sites in the lip, oral cavity and pharynx [ICD-O-3:C14] 
8. Larynx [ICD-O-3:C32] 
9. Carcinoma unknown primary with secondary neck nodes [ICD-O-3:C77.0] 
 
Incidence and prevalence: 
Malignancies of the head and neck sites are leading sites in all the cancer registries in 
India as per the consolidated report of the population based cancer registries(5). The estimated 
Age standardised incidence Rate (ASR) of head and neck cancers per 100,000 populations in 
India is one of the highest. The ASR for Indian males is 19.6 compared to the global average of 
10.4, and Indian females 7.2 compared to 4.2 as per the GLOBANCAN 2008(6) database of the 
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IARC-WHO (International Agency for Research on Cancer- World Health Organization). Indian 
cities (Bhopal) have the highest incidence of oral malignancies in the world (7).  
The major reason for such prevalence of head and neck malignancies is generally 
attributed to the use of tobacco, especially smokeless tobacco which is highly prevalent in India. 
33% of the tobacco consumed in India is of smokeless variety (8), whereas in the west 85% of 
the tobacco is used in production of cigarettes alone. India is the third largest producer of 
tobacco in the world with an annual production of about 725 million kg (9) as per the Tobacco 
Board; Government of India. It is in excess of the estimated tobacco production by FAO (10) 
which was 685 million kg by 2010. The National household survey for Drug and Alcohol abuse 
in India reported, massive, 55.8% tobacco users, among males of the age group of 12-60 years 
(11). External beam radiation is an important tool for the treatment of Head & neck malignancy 
either alone or in combination with surgery and chemotherapy.  
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Thyroid gland 
Thyroid gland is an endocrine gland situated in the anterior neck. It extends superiorly from 
the laryngeal prominence, inferiorly up to about 4 cm below the cricoid cartilage extending 
laterally about 3.25 cm bilaterally from the midline.(12) Due to its position it is nearly always 
irradiated while the neck is being irradiated for any head and neck malignancies.  
 
Thyroid hormone: 
The primary function of the thyroid gland is to produce thyroid hormones which include 
thyroxin (3,5,3′,5′-tetraiodothyronine) and 3,5,3′-triiodothyronine. 
 
Fig-2.1: structure of T3 and T4(13) 
 
 
The thyroid gland through a membrane glycoprotein called the sodium-iodide symporter (NIS 
or SLC5A) concentrates iodine from the plasma (14). This process is an active symport of the 
Iodine through the membrane against the gradient.  This process is known as iodine tapping. 
Moreover, the iodotyrosine dehalogenase (Dhal) enzymes, also generates intracellular iodide 
resulting in increased iodide concentration in the thyroid gland (13). 
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Fig-2.2 synthesis of the thyroid hormones (13) 
 
The iodide is then oxidized and organified. The process of organificantion results in 
incorporation of oxidized iodide in hormonally inactive iodotyrosines MIT and DIT [Mono- 
iodo- tyrosine and Di-iodo-tyrosine].  TPO (tyrosine per-oxidase) catalyses the fusion of two 
molecules of TG bound DIT to result in formation of T4 and the fusion of MIT with DIT results 
in formation of T3. This reaction is called a coupling reaction.  The thyroid hormones so formed 
are stored in the cells of thyroid glands and are released in the blood.  
The thyroid hormones belong to the group I hormones which act on the intercellular receptors 
(15). These receptors are known as thyroid receptors (TR). The hormone receptor complex so 
formed attaches itself to the DNA via a zinc finger motif and exerts its physiological effects.(16)   
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The thyroid hormones have a wide range of physiological function. It increases the metabolic 
activity and oxygen consumption in most of the tissues except brain, heart, testis and retina. Thus 
it is calorie genic.  On heart it is both inotropic and cronotropic,. It is pro developmental in the 
brain and the neural tissues, has catabolic effect on the adipose tissue. It increases the 
metabolism in Gastro-intestinal tract and the lipose tissue. (17) 
Hypothyroidism and types: 
Hypothyroidism is deficiency of the thyroid hormones either due to lesser production of 
the thyroid hormones or end organ resistance to it. This was first described by Gull in 1874.(18). 
Hypothyroidism is caused due to either impaired functioning of the thyroid gland, or due to 
impaired stimulation of the thyroid gland due to low levels of thyroid stimulating hormones. The 
lesser production of the hormones by the thyroid gland itself despite adequate amount of TSH is 
termed as primary hypothyroidism. The insufficient stimulation of the thyroid gland can be a 
result of the malfunctioning of the pituitary or hypothalamus or due to defects in the thyroid 
stimulating hormones (TSH) molecules. (19) 
Primary hypothyroidism has been divided into clinical and subclinical hypothyroidism. 
This division is not based on presence or absence of the clinical features of hypothyroidism. 
Subclinical hypothyroidism has been defined as patients with elevated TSH levels with normal 
or low normal free T4 levels (20). It has been also described as preclinical hypothyroidism, mild 
hypothyroidism, early thyroid failure, and decreased thyroid reserve by various authors (20). 
Though called subclinical it may be associated with clinical symptoms or signs those akin to 
clinical hypothyroidism (21) 
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Historical perspective of hypothyroidism: 
 
Hypothyroidism has been documented to be of common occurrence in the post RT 
period.  Grover in 1929(22) was the first to suggest decrease in thyroid function following 
exposure to radiation.  Felix et al (23) was one of firsts to document hypothyroidism in head and 
neck malignancies (carcinoma larynx) treated with radiation therapy. 
 
Reasons of development of post radiotherapy hypothyroidism: 
 The reasons of development of hypothyroidism in such patients has been documented as 
follows- 
1. Direct radiation damage    
2. Small vessel damage  Fibrosis of capsule (24)(25)     
3. Relative ischemia due to RT induced carotid artery atherosclerosis(26) 
4. Relative ischemia due to RT induced carotid artery atherosclerosis(25) 
5. Change in size of the thyroid gland(25)  
6. Development of anti-thyroid antibodies(27) 
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Incidence – World and India: 
The incidence reported in literature is very varied. Most of the information that is 
available is western data based on Caucasian and Afro- American patients. Data from a few 
Indian studies is available.  As it is noted in western literature, the incidence and severity varies 
between Caucasians and Afro-Americans (28) the western data may not be applicable to the 
Indian scenario. Incidence including India 
 
Prevalence of hypothyroidism in general population: 
The incidence of hypothyroidism in India has been found to be more compared to that of 
western population. A cross sectional study conducted in Chennai by Shantha et al(29) showed 
an incidence of 8.8% of hypothyroid patients in groups who were otherwise healthy[ i.e., no 
features of Metabolic syndrome]. 
 
Incidence of hypothyroidism in post radiotherapy patients: 
The incidences of hypothyroidism after radiotherapy for head and neck malignancies as 
documented in some of the literature are as follows:- 
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Table- 2.1- 
Incidence of hypothyroidism after radiotherapy for head and neck malignancies 
Author Published in incidence 
Alkan et al 2008(30) Otlolaryngol Head neck surg 
139,787-91 
49.3% 
O cetinayak 
2008 (31) 
Tumori 94:19 40% 
Bhandare et al 2007 
(32) 
Int J Radiat Oncol Biol Phys 
64,4.1131-1139 
29%-subclinical 
32%(clinical) 
Alterio et al 2007(33) Int J Radiat Oncol Biol Phys 67, 1. 
144-150 
26% 
Tell et al 2004(34) Int J Radiat Oncol Biol Phys 60, 2. 
395-400 
17%(overt) 
Mercado et al 
2001(28) 
Cancer 92: 2892-7 48% 
Sinad et al 2000(35) Arch otlolaryngol head neck surg -
126, 652-57 
14.6% 
Turner et al 1995(36) Int J Radiat Oncol Biol Phys 31, 2. 
279-283 
23.8% 
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Cannon et al 1994 
(24) 
Laryngoscope-104 15% 
Tami et al 1992 (2) Am j Otol -13 45-68% 
Hancock et al 1991 
(37) 
N eng J med 1991 325: 599-605 47% 
Buisset et al 1991 
(38) 
Ame j o surg 162;345-347 34% 
Lening et al 1990(39) Otlolaryngol Head neck surg -13 6-28% 
Posner et al 1984 
(40) 
Laryngoscope 94 37% 
Tamura et al 
1981
 
(41) 
Cancer 47(11): 2704-11 26% 
Estefan et al 
2009 (42) 
Acta Otorrinolaringol 
Esp.2009;60(4):268-271 
36.4% 
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Post radiotherapy hypothyroidism In Indian Patients: 
  Data regarding the incidence in Indian patients are mostly from those undergoing 
conventional irradiation. Available Indian data for conventional radiotherapy shows 17.8 % 
and 21.8 % were found to have clinical and sub-clinical hypothyroidism at two year (3) , 
about 3.6% at 6 months and 0.57 % at 6 weeks.  Moreover routine evaluation of TSH and TFT 
has not been started on a regular basis in India. 
  Unpublished data presented in AROI TN CON 2009 by Dr. T Sujit et al (43) showed an 
overall incidence of 20% at 12 months with a mean duration of onset at 7.2 months (range 4.3 
to 9.7 months). 
  Regarding our patients who are treated in our institute, there is no prospective data 
regarding the occurrence of hypothyroidism. In early 1990’s Dr.Jaylakshmi (44) (thesis no 
D825 CMC Vellore DODD library -1992) had done a retrospective study on development of 
hypothyroidism in patients receiving radiation therapy to neck for any cause including 
lymphoma, by conventional planning only with 100% of the thyroid volume within the 
irradiated fields. It showed an incidence of 16% on long term follow up. Being a retrospective 
study the onset of the thyroid dysfunction could not be determined.  
  However the study is limited by the fact that a lot of patients today receive conformal 
radiotherapy and the radiation fields may not be including the whole of the thyroid gland or 
that the whole of the thyroid gland may not be irradiated with uniform dosage.  Most of our 
patients today who receive radiation to the neck belong to the subgroup of carcinomas and not 
lymphomas (66% of the patients were lymphoma patients treated with mantle field irradiation 
in that study).   (44) 
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Time for development of hypothyroidism 
  The time to development of hypothyroidism has varied across the studies. It has ranged 
from weeks to years. However, most patients developed the problem in months.  Alkan et al 
(30) showed the average duration of onset was at 6.08 months and 83 % of the patients who 
developed hypothyroidism developed within 9 months.   
  Nishiyama et al (45) has described significant rise since 4th month and 6th month from 
starting of radiotherapy (~4.5 months from completion of RT). The mean TSH was 7.57 
(compared to the baseline TSH of 1.53(+/-1.01) mU/ml). The elevation was noted in 17 out of 
22 patients, and was statistically significant (P=0.003). This increase of TSH was much earlier 
than those found in the western literature.    
  Available Indian data by Aich et al (3) showed an incidence of 0.57% at 6 weeks post 
radiotherapy
 
3.6% at 6 months post radiotherapy.   
   Sinad et al
 
(35)
 
found the average time of development of hypothyroidism to be about 8.2 
months (with a range of 1-21 months). In 83% of the cases it was evident by 12 months.  
However some patients may become hypothyroid even after years of treatment.   
  Most of the other western studies [with American and European population] have looked 
into the long term consequences and have found that the onset of hypothyroidism can occur 
even decades after the treatment with radiation therapy to head and neck region. 
  Turner et al
 
(36) commented that there is no clear correlation between the degree of 
thyroid dysfunction and time from radiation & that it may occur, early following treatment.  
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 Role of co-factors in development of hypothyroidism:   
 
 Age-  
  The relationship with development of post radiotherapy hypothyroidism has been found 
to be inconclusive.  Hancock et al (37) had shown that the chance of development of 
hypothyroidism is more in the younger and paediatric age group. 
 Sex-   
   Female sex has been found to be a significant co-factor in development of 
hypothyroidism by some researchers
 
(30)(37)
 and 
(40)
.
 However other authors have shown that 
there were no statistically significant difference between the event and female sex.  Aich et al 
(3) in his study among the Indian patients did not find any significant difference. 
Chemotherapy-  
  Though chemotherapy has been much mentioned as a probable additional factor for 
toxicity, a lot of literature did not support a difference in development of hypothyroidism.  
However, in his study by Kurten (46) et al showed that patients who receive chemotherapy for 
Hodgkin’s’ Disease has a lower threshold for developing hypothyroidism (<40Gy).   The 
Indian study by Aich et al (3) did not show any relation with administration of neo-adjuvant or 
concurrent chemotherapy.   
 Smokers:-  
  There is no conclusive evidence that smoking affect the incidence of hypothyroidism. 
However some argue that smoking might aggravate the vessel damage leading to 
hypothyroidism in post RT patients.   
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 Surgery: -    
  Alterio et al (33) did not find any difference in occurrence of post RT hypothyroidism in 
patients who had undergone surgery compared to those who have not. On the contrary Turner 
et al(36)
 
(P<.001) Gande c (47) P=.003 and Posner et al(40)  (incidence of hypothyroidism 
was 43% vs. 30%) did find neck surgery to be of significant influence for development of post 
radiotherapy hypothyroidism. Smith et al (48) in their population based study of older patients 
(> 65 years at the time of onset of disease) found that there is no significant statistical 
difference in development of hypothyroidism in patients treated with RT alone VS., RT and 
surgery. (P=0.15). Though it clearly showed a significant increase in incidence of 
hypothyroidism in between patients treated with RT and surgery VS., Surgery alone (p<.001) 
and RT alone VS., surgery alone. (p<.001).  In his study, neck dissection was not a modifying 
factor for incidence of hypothyroidism.  There has been some evidence to show that the type 
of neck surgery patients undergo does affect the incidence of development of hypothyroidism.  
Tami et al (2) in his study did find a significant difference between the incidence of 
hypothyroidism in patients who had undergone neck surgery [45% those who had undergone 
(surgery compared to 29% in patients who did not have any surgery.]. On subset analysis, the 
patients who did not have any laryngectomy during surgery were found to have an incidence 
of 28% suggesting that surgery involving laryngectomy is a factor in development of post RT 
hypothyroidism.  Cetinayak et al (31) in his study has shown that there is no role for neck 
dissection in development for hypothyroidism but for surgeries involving thyroid gland.  
  Sinard et al (35) in their study had found that non laryngeal surgery does not change the 
incidence of development of hypothyroidism as in neck dissection. Even with partial 
laryngectomy, there is no change in incidence. Patients who had undergone total 
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laryngectomy with thyroid lobectomy, the incidence is much higher at 61% compared to 48% 
in patients who did not have any surgery (P<.001).  
 
Relationship with radiotherapy dose and volume: - 
   Being a parallel organ, thyroid dysfunction depends both on the volume and dose of 
irradiation.  Different studies have explored the option of tolerance dose of the thyroid and the 
volume. However the relationship is yet to be definitely established (49).  Emami et al
 
(50) 
had noted, tolerance values of 8/5, 13/5, and 35/5, i.e. incidence of clinical hypothyroidism 
respectively in 8%, 13%, and 35%  of patients after 5yrs of radiation therapy when the dose 
received are 45 Gy, 60 Gy, and 70 Gy respectively. However, this data does not give us any 
idea with relation of the volume of thyroid gland irradiated and is therefore valid only when 
the whole of the thyroid gland is within the field of radiation and  is uniformly irradiated, 
which is not the case in most of the modern era of conformal radiation and IMRT.  Hancock et 
al (37)
 
in their study has shown that the risk of developing increases to 40 % in patients 
receiving >30 Gy compared to 12% for patients receiving less than that.  In a study by Kurten 
et al(46) the authors showed that there is a similar rise of risk from 27% for patients receiving 
a dose lesser than 45 Gy compared to 40 % for doses >45 Gy.    
  Including the thyroid in the low-neck field to 50 Gy results in hypothyroidism in 30% to 
50% of patients at 5 years,  was found in a study by Norris AA et al(51), suggesting  that the 
threshold for this complication is <50 Gy.    
  Alkan et al (30) 
 
had shown in their study that dose received by the whole of the thyroid 
gland is a significant risk factor. The dose received to the whole of the thyroid gland in their 
study was 6.07 +/- 35 Gy in the patients who had developed hypothyroidism was significantly 
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higher than the group who remained euthyroid, which was 5.92 Gy +/-25 Gy (p<.05). 
  Bhandare et al (32)
  
the incidence of hypothyroidism increases by 16 % for doses more 
than 45 Gy.   
  The study noted that if the treated volume >=85%then the chance of developing clinical 
hypothyroidism was 23% compared to 0% when the treated volume is < 50 %.  The incidence 
of subclinical hypothyroidism was 25 % and 10% for bilateral and unilateral neck nodes 
irradiation respectively.  
  Using Dose Volume Histogram (further referred as DVH), Alterio et al (33) 
 
did not find 
any relationship between the irradiated thyroid volume and dose, with respect to V10, V30, 
and V50. When V10, V30, V50 are thyroid volumes irradiated by a dose of over 10, 30 and 50 
Gy respectively.  As per the authors however, the scope of use of DVH in their study was 
limited by the act that the study cohort had a relatively uniform DVH.  Yoden et al (52) in 
their study found V10-60 (percentage of volume of thyroid gland receiving radiation doses 
between 10 Gy and 60 Gy) to be a possible risk factor.  They also reported that V30 
(percentage of volume receiving > 30 Gy) was a predictor of peripheral hypothyroidism. It 
was also found to be a significantly correlating with peak serum TSH levels.   
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  Presentation of radiation induced hypothyroidism-  
  The general features of hypothyroidism include depression, lethargy, early fatigability, 
general malaise, anhedonia, dry skin, constipation. (42), (27). Due to concomitant presence of 
such events in cancer survivors, they often tend to get looked over. (27)This is more in cases 
of patients belonging to the weaker socio-economic status where such symptoms are generally 
attributed to the prevalent social condition and or loss of economic security. Moreover, due to 
these confounding symptoms relaying on clinical examination for detection of post 
radiotherapy hypothyroidism may not always be useful (27). However, these symptoms are 
important from the perspective of the patient and his or her family members as they impair the 
quality of life and prevent rehabilitation of the patient and the family not only from the view 
of health but also from the view of  economic rehabilitation and social reintegration of the 
patient and the family.  The first because of loss of economic productivity and the later by 
prolonging and reinforcing the stigma associated with cancer survivorship.  
 
  Treatment and Quality of life: 
  Thus hypothyroidism does affect quality of life (QOL) in cancer patients and cancer 
survivors, to whom it matters the most.  However it can be easily treated by exogenous 
supplementation of thyroxin at low cost. The cost of thyroxin supplement of 100 mg per day 
entails a retail cost ranging from   0.80 to  1.26 per day depending on the manufacturer. 
The bulk cost is even lower at  0.27 (53).  Tests to detect hypothyroidism are available 
(TSH/ TFT) but are not routinely used in post radiotherapy patients in countries like India.   
 
  Exogenous supplementation of levothyroxine is required for clinical hypothyroidism. 
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Supplementation of levothyroxine improves the symptoms in the symptomatic patients who 
have subclinical hypothyroidism [i.e. Biochemical hypothyroidism].  Moreover, it has been 
shown that subclinical hypothyroidism causes cardiac dysfunction even when the patient is 
absolutely asymptomatic and supplementation of levothyroxine results in improvement of the 
same (54).  The increased risk of coronary atherosclerotic disease has been documented in 
patients of subclinical hypothyroidism by some studies. These include the Rotterdam Study 
which showed significantly increased prevalence of aortic atherosclerosis and consequently 
myocardial infraction (55) in elderly female patients with subclinical hypothyroidism.  Danese 
et al in their quantitative review of literature (56) showed that the treatment with 
levothyroxine supplementation results in lowering of mean serum total cholesterol and LDL 
cholesterol concentration.   The Chrocrane review on supplementation of levothyroxine for 
sub-clinical hypothyroidism showed some evidence that such replacement improves some 
parameters of lipid profile and LVF (57).   
 
 Guidelines for post radiotherapy screening: 
  There is no standard universal guideline regarding the monitoring of thyroid function post 
radiotherapy. NCCN (58)
 
 recommends monitoring TSH and TFT in post RT patients treated 
with radiotherapy with head and neck malignancies every 6-12 months, in cases where the neck 
is irradiated.  ESMO (59) recommends the same at 1 year, 2 year and at 5 years post radiation 
therapy. The ESTRO/TMH international symposium 2005(60) recommended monitoring of T3 
T4 and TSH annually for post op patients particularly in patients with laryngeal malignancy.  
However, even in developed countries like Netherlands the most of the monitoring (75%) is done 
only when the patients complain of symptoms. In a nationwide survey carried out in Netherlands 
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by Galbo et al (61) biannual monitoring of TSH was done by only 24% of the physicians 
involved in the follow up care of the patients who had undergone radiotherapy for laryngeal 
carcinoma.    
 
  These guidelines (NCCN, ESMO etc.) are based on the western data; and the need in 
Indian patients might differ in terms of time and frequency of the monitoring.  In our 
institution, we generally advise monitoring during the follow up period with TSH at each 
follow up, i.e., 6 weeks, 19 weeks, 32 weeks, 45 weeks and 58 weeks after completion of 
radiotherapy and thereafter every 6 months at the time of follow up. 
 
  Moreover, while ordering a test for monitoring in our patients, we always have to be 
aware of the resource constraints.  
   
  Data regarding Indian patients are scarce especially for those who undergo conformal 
radiation.  There is need to know the incidence of hypothyroidism and the factors influencing 
the same. Such data can help us to identify the patients who need to be intensively followed 
up and judicious use of resources can be done.   
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Study subjects- 
Inclusion criteria:- 
1. Adult patients[ more than 18 years of age] with non-metastatic Head & Neck 
carcinoma, without any intracranial extension,  of the following sites- 
a. Nasopharynx  
b. Sinonasal cavity 
c. Oropharynx 
d. Oral cavity 
e. Hypopharynx  
f. Larynx  
g. CUP [Carcinoma of unknown primary] 
2. Patients receiving radiotherapy(>45 Gy) as part of treatment 
3. Radiation field extending to lower neck , unilateral or bilateral 
4. Performance score- 0 to 2 
Exclusion criteria:- 
1. Known to have hypothyroidism  
a) At the time of screening  
b)  The history of hypothyroidism in the past, for which he/she is currently 
on supplements. [Hypothyroidism was defined as TSH more than the 
maximum of the normal range, or TSH >4.5 micro IU/ml]. 
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2. Who has a history of previous exposure to radiation therapy in Head and neck 
region 
3. Carcinomas with intracranial extension by clinical or radiological examination. 
Target sample size calculation:- 
 Target sample size was calculated based on the following formula- 
Required sample size= 4 PQ/ d
2
 
When P= likely incidence, d= expected deviation from the incidence 
Q= 100-P 
Considering the incidence of hypothyroidism in post radiotherapy patients in Indian population 
be around 15 % and the range being around 5-25 % [i.e., deviation of about +/- 10 %] 
P= 15 
Q= 100-15=85 
d= 10 
So, calculated sample size= (4 x 15 x 85)/ 10
2 
=
5100/100       =51 
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Materials:-  
1) Informed consent document English  [annexure-2] 
2) Translations of informed consent documents  
a. Tamil- annexure 3 
b. Hindi-annexure 4 
c. Bengali- annexure 5 
3) Standard thyroid questionnaire –annexure 6 
4) Thyroid questionnaire -2 [annexure 7] 
5) Quality of life questionnaire –FACT H& N [annexure 8] (62) 
6) Thrermolumisent dosimeter [TLD][fig-] 
7) TLD holder [fig-] 
8) Treatment machines- Theratron 780C[cobalt 60 tele-therapy machine –theratronics], 
Primus [Lenier accelerator –simens] 
9) Simulator-  
10) CT machine for CT in planning position [planning CT]- simens 
11) Treatment planning system – Oncentra, Plato, Aria. 
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Methods:- 
 The patients who fulfills the above mentioned criteria , were explained about the aims, 
objectives, protocol, investigations, required for the study both verbally and by a written 
informed consent document, as approved by the institutional review board and ethics committee 
[hereafter referred as IRB] in a language patient can understand. Their doubts and queries, if any, 
answered. As and when required, help of translators, who are well versed with the present study, 
were taken.  
After the informed consent is obtained, they were screened for any thyroid abnormalities. 
The screening tests include the followings:- 
a. Blood for TSH 
b. Blood for TFT [T4 and FTC] 
They were also asked to fill up the following questionnaires’:- 
a. Standard thyroid questionnaire -1 (27) 
b. Thyroid questionnaire -2[ as generated by CMC] 
c. Quality of life questionnaire- FACT H & N 
Once they are found to be fitting into the euthyroid group by the blood tests. They were 
included as the part of the study. Patients, who were found to be hypothyroid on investigations, 
were not included in the study. They were referred to the Department of Endocrinology for 
further evaluation and necessary management.  
The patients were started on treatment as required as per their treatment plan and 
modality of radiation chosen by the patients [conventional 2D cobalt, 3 DCRT, IMRT] with or 
without chemotherapy, with or without biological agents.  
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While on treatment the measurement of the point dose to the thyroid region was done. 
The points of measurements were based on the surface marking of the thyroid gland (12) as 
follows- 
Isthmus-  
i. A point in the midline, 1 cm below the arch of cricoid cartilage and a horizontal 
line of 1.5 cm is drawn across the trachea. This line represents the upper border of 
the isthmus. 
ii. A second point 1.25 cm below the first is taken and a 1.5 cm horizontal line is 
drawn. This line represents the lower border of the isthmus. 
Lateral lobes of the thyroid  
i. A point is taken 1 cm below the lower border of the isthmus at the lateral most 
point. 
ii. A point is placed 2.5 cm lateral of the point (i) 
iii. A point is placed at the level of laryngeal prominence on the anterior border of 
the sternocledo mastoid. This point represents the upper pole of the thyroid 
gland. 
The lateral end of the line representing the lower border of the isthmus is joined to point 
(i) and point (ii) is succession with the convexity of the line towards the caudal end. This 
would be representative of the lower pole of the thyroid gland.  A line is used to join the 
upper pole and the upper border of isthmus in its lateral most aspect.  Another line is used 
to join the lateral most point of the lower pole and the upper pole. 
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Fig-3: surface anatomy of the thyroid gland (12)  
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Based on this surface anatomy, the points for measurement of point dose to the thyroid 
were made. The points were as follows:- 
i. A   point 1 cm below the thyroid notch at the anterior border of the sternocledo 
mastoid muscle point 1(right) and point 2(left) to represent the right and the left 
upper poles of the thyroid. 
ii. A point at midline, at the midpoint of the thyroid notch (laryngeal prominence) 
and sternal notch, representing the isthmus of the thyroid- point 3.  
iii. A point 3 cm below the cricoid cartilage and 2 cm from the midline so as to 
represent the right (point 4) and left (point 5) lower poles. 
The points are shown in the figure 2. 
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Fig-4: points for measurement of the point dose to the thyroid gland. 
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Fig- 5: longitudinal view of TLD holder  
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Fig 6- lateral view of the TLD holder  
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The measurements were done with the help of Thermoluminisent dosimeters (herein 
referred as TLD). The TLDs were placed in a specially placed TLD holder made of persplex. 
The holder is cylindrical in appearance with one side flattened so that the holder can be easily 
placed over the body or the ray cast of the patient. The dimension of the holder was 1 cm in 
diameter and 2 cm in length. A cylindrical hole is drilled at 0.5 cm from the flat surface along the 
axis of the holder so as to allow two TLD chips to hold snuggly in position. [Fig 3, 4] 
The TLDs were calibrated and data generated for measurement.    
 
At the end of RT the following assessment was done –  
a. Standard thyroid questionnaire -1 
b. Thyroid questionnaire -2 [ as generated by CMC] 
c. Quality of life questionnaire- FACT H & N 
d. Clinical assessment of disease status 
The patients were followed at the following time schedule 
a. At 6 weeks form the date of completion of radiotherapy 
b. At 18 weeks [4.5 months] from the date of completion of radiotherapy 
c. At 30 weeks [7.5 months] from the date of completion of radiotherapy 
An allowance of +/- 2 weeks in each follow up, to allow for any personal, 
physical, social, economic, or environmental  inconvenience  beyond the control of the 
patients. This was kept especially in view of the patients who come from the remote areas 
and distant places.   
In cases the patient did not turn up within the specified limit, an attempt was made 
to contact the patient to ascertain the reason and the condition of the patient. 
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At these follow up the following were done:- 
a. Standard thyroid questionnaire -1 
b. Thyroid questionnaire -2 [ as generated by CMC] 
c. Quality of life questionnaire- FACT H & N 
d. Assessment of disease status- clinical and radiological if necessary 
e. Blood for TSH and TFT (FTC and T4). 
Patients were then classified into groups as per their results of the blood tests.  
Hypothyroidism as defined biochemically or sub clinically as raised TSH only 
(normal-0.3 to4.5), or clinical hypothyroidism with raised TSH and a low T4 
(normal- 4.5- 12.5), free T4 (.8 to 2). 
 
 
 T4 <4.5m g/dL 
or 
FTC<0.8 
T4>4.5m g/dL 
and 
FTC>0.8 
TSH¬ 
> 4.5m 
IU/ml 
 
Clinical primary 
hypothyroidism 
Subclinical primary 
hypothyroidism 
<4.5m 
IU/ml 
 
Central primary 
hypothyroidism 
euthyroid 
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 The thyroid questionnaire was given to the patient for self-administration with or without the 
help of the investigators. Both the standard and the generated questionnaires were in Likert scale. 
Likert scale is psychometric one-dimensional scaling method invented by Resnis Likert.(63). A 3 
point scale was used for these questionnaires. The standard questionnaire was taken from the 
standard used by Galbo et al (27). 
 For the purpose of measurement of QOL, the FACT H & N questionnaire (62) was used. This 
is a standard questionnaire and had been used and validated by various investigators.(64)(65). 
This questionnaire was also based on Likert scale. This self-administered scale contained both 
subsets of questions for physical, emotional, functional, social wellbeing and a head and neck 
section. While calculating for the scores, the scores for the negative questions were subtracted 
from the maximum possible score (=4) before adding to the final scale.(66).   
 The results were then tabulated and analysed. 
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Screening data - 
In the current prospective study 60 patients were screened. Out of these patients 7 
patients did not fit into the eligibility criteria due to age [1 patient -1.67%], re irradiation [2 
patient s-3.33%] and intracranial extension [4 patients -6.67%]. [Table-1] 
. 
 Table-5.1 
TOTAL NO PATIENTS SCREENED 
Total 60 [100%] 
Pediatric age group 01[1.67%] 
Re-irradiation 2[3.33%] 
Intracranial extension 04[6.67%] 
Eligible for screening tests 53[88.33%] 
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Table – 5.2 
Prevalence of hypothyroidism among the screened patients 
 Numbers 
Total  53[100%] 
Initial hypothyroid Sub-clinical 6 [11%] 
Clinical 0 
Initially euthyroid 47[88.68%] 
 
Out of those consented for screening for hypothyroidism, 6 patients or 11% were found 
to be hypothyroid. All the 6 patients had subclinical hypothyroidism based upon biochemical 
parameter (TSH, T4 and FTC). [Table 2: Screening data]. The rest [47 (88.68%)] were eligible 
for inclusion into the study 
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Figure:-5.1: prevalence of hypothyroidism in the screened population 
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Demographic parameters: 
Age and Sex- 
The age and sex distribution is showed in the table –3. 
Table-5.3 
Distribution of the study population according to age and sex 
 Male Female Total 
18-40 2[4.88%] 2[33.33%] 4[08.50%] 
41-60 26[63.41%] 4[66.67%] 30[63.83%] 
>60 13[31.70%] 0 13[26.66%] 
Total 41[87.23%] 6[12.77%] 47[100%] 
 
Among those enrolled in the study, There were 41 males and 6 females enrolled for the study. 
The males comprised of 87.23 % and females only 12.77 %. As per age group there were 30 
patients[63.68%] belonged to the age group of 41 to 60 years, 13 patients were above 60 years 
[26.66%] and only 4 patients [8.5%] were lesser than 40 years of age. 
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Place of domicile-.  
The study cohort was a mixed cohort of patients residing at the costal and Himalayan regions of 
India.  
Fig-5.2: 
 
Most of the patients were from the coastal region of India. There were 5 patients from the 
sub Himalayan region, which accounted for 10.65% of the study population 
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Addiction habits:- 
Data, regarding the addiction data was also collected and analysed.  
Table-5.4: Addiction habits among the study population 
Addiction type Frequency Percentage 
Smoking  only 6 10.64% 
Chewable tobacco /beetle 
nut 
3 06.38% 
Both 16 34.04% 
Pan 2 04.26% 
No addiction 21 44.68% 
Total  population 47 100% 
 
There were 20 [44.68%] patients in the study group who were smokers. They had 
however, quitted smoking after being diagnosed of having malignancy. 16 of them [34.04%] 
were also addicted to either chewable tobacco or beetle nut. In addition, another 2 patients were 
addicted to Pan [beetle leaf]. 
  
50 | P a g e  
 
Fig-5.3: Distribution of patients according to sex 
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Comorbid factors:- 
 The co-morbid factor of hypertension and diabetes mellitus was recorded. 
Table-5 
Distribution of patients according to co-morbidities 
 Yes  No  Total  
Hypertension 6[12.77%] 41 47 
DM 2[4.55%] 45 47 
 
Among the 47 patients 6 patients [12.77%] had hypertension and were on treatment with 
anti-hypertensive, while 2 [4.55%] were diabetic and were on OHAs. None of the patients were 
on regular use of insulin in this study group. 
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Fig-5.4: baseline TSH levels plotted as histogram 
 
 
 
 
The baseline TSH data was plotted in form of histogram which showed a near normal 
distribution of the TSH values with mild skew to the left.    
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Disease characteristics:- 
Site of the disease- 
The patients in the present study were distributed across various sites of the head and neck 
malignancy.  
Fig-5.5: Pie chart showing distribution of patients according to the primary site of 
disease. 
 
Among the various sub-sites, larynx was the most common site with 38% [or, 13 patients] of the 
total study population. Oral cavity [13, 28%], Hypopharynx [7, 14.91%] and oropharynx [6, 
13%] were the other commonly occurring site. 
Oral cavity 
28% 
Oropharynx 
13% 
Nasopharynx 
4% 
Hypopharynx 
15% 
Nasal cavity 
2% 
Larynx  
38% 
Distribution of patients according to the primary 
site of disease 
18 
13 
6 
2 
7 
1 
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Stage of the disease with primary:- 
Majority of the patients in the study group[31 out of 47] were of locally advanced nature 
with stage III and IVa, making up the 66% of all patients.  It gives an indication that our patients 
present late in the course of disease. 
Among the various disease sites, the patients with laryngeal carcinoma presented 
relatively early. 12 of the 18 patients of carcinoma larynx [66% of the patients] belonged to the 
stage I and II, in contrast to the rest of the sites where, only 4 out of 29, i.e. 13.8% belonged to 
stage I and II. This may be due to early impairment of functionality of the patient.  
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Table –5.7 
Distribution of stages according to the disease primary 
 I II III IV a Total 
Nasopharynx  0 0 0 2[100%] 2[100%] 
Nasal cavity and 
PNS 
0 0 1[100%] 0 1[100%] 
Oral cavity 1 
[7.69%] 
1 
[7.69%] 
4 
[30.77%] 
7 
[53.85%] 
13 
[100%] 
Oropharynx 0 0 3[50%] 3[50%] 6[100%] 
Larynx 4 
[22.22%] 
8 
[44.44%] 
4 
[22.22%] 
2 
[11.11%] 
18 
[100%] 
Hypopharynx 1 
[14.26%] 
1 
[14.26%] 
0 5 
[71.43%] 
7 
[100%] 
Total 6 
[12.77%] 
10 
[21.28%] 
12 
[25.53%] 
19 
[40.43%] 
47 
[100%] 
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Pre radiotherapy surgical intervention:- 
 Fig-5.6: Distribution of patients as per the pre radiotherapy surgical 
intervention. 
 
There were 7 patients, [14.89%] who had undergone surgical intervention for the present 
disease condition with intent of treatment. Among them 4 [57.14%] had modified radical neck 
dissection and 3 [42.84%] wide local excision.   
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The distribution of the surgical intervention as per disease site, and type is as 
follows- 
Table-5.8 
Distribution of the surgical intervention as per disease site. 
Stage  WLE MRND 
 Oral cavity  Nasal cavity & 
PNS 
Oral cavity Nasal cavity & 
PNS 
1 1[50%] 0 0 0 
2 0 0 0 0 
3 0 0 1[25%] 0 
4 1[50%] 1[100%] 3[75%] 0 
Total  2[100%] 1[100%] 4[100%] 0 
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Evaluation status of the patients:- 
Table -5.9 
Present status of the patients recruited 
status Number (Percentage) 
Completed 3
rd
 follow up 6[12.73%] 
Completed 2
nd
 follow up 14[42.55%] 
Completed 1
st
 follow up 17[78.72%] 
Not completed 6 weeks post RT- 3[6.68%] 
Loss to follow up( incl. death) 7[14.89%] 
total 47 [100%] 
 
Among these patients, there are 3[6.38%] patients who are yet to become evaluable.  There have 
been 7 [14.89%] patients whose follow up data is not available due to either death (1) or loss to 
follow up. Rest 37[78.72%] patients have come for follow up. Out of those who have come 14 
[29.68%] have completed their second and 6[12.77%] have completed their third follow up 
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Incidence of hypothyroidism:- 
Table-5.10 
Distribution of patients who have come for follow up according to their thyroid 
status and time to development 
 
Time of review Total reviewed hypothyroid percentage 
6 weeks 37 3 08.10 
19 weeks 20 2 10.00 
32 weeks 6 0 0.00 
Total 37 5 13.51 
 
Till date 5 patients [13.51%] have developed hypothyroidism. Out of them 3 [8.1%] had 
developed hypothyroidism on the 1
st
 visit i.e., at 6 weeks from the completion of radiation 
therapy 
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Fig-5.7: Distribution of patients according to their thyroid status 
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Fig-5.8: 
Event free follow up [1-probabilty of developing hypothyroidism] against time 
 
Probability of development of iatrogenic hypothyroidism after radical radiotherapy X 
axis indicates duration in weeks and Y axis indicates event free probability.   
The probability of iatrogenic hypothyroidism as estimated by this is 10% at 10 weeks and 22% at 
20 weeks,   
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The patients were evaluated with TSH, T4 and FTC.  
The distribution of the same is shown in the following tables- 
Table-5.11 
Distribution of TSH of hypothyroid patients at various time frames 
TSH Mean Std. dev. minimum maximum Range  
Baseline  3.1100 .868 1.79 4.20 2.41 
1
st
 Fu 6.9380 5.114 .63 12.89 12.26 
2
nd
 Fu 24.885 10.98 17.65 32.65 15.53 
 
 
Table-5.12 
Distribution of T4 of new hypothyroid at various time frames 
T4 Mean Std. 
deviation 
minimum maximum Range  
Baseline  9.24 1.93 7.60 12.30 4.70 
1
st
 Fu 7.78 1.08 6.0 8.70 2.70 
2
nd
 Fu 6.15 .071 6.10 6.20 0.10 
 
Table-5.13 
Distribution of FTC of new onset hypothyroid patients at various time frames 
63 | P a g e  
 
FTC Mean Std. dev. minimum maximum Range  
Baseline  .9860 .1176 .81 1.10 .29 
1
st
 Fu .9020 .12637 .76 1.10 .34 
2
nd
 Fu .7250 .06364 .68 .77 .09 
 
Fig-5.9:Distribution of hypothyroidism as per type and duration of 
occurrence.
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Out of the 5 patients who had developed hypothyroidism 3 had clinical hypothyroidism 
and 2 had subclinical hypothyroidism. Both the patients who had developed subclinical 
hypothyroidism were detected at 6 weeks. 
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Distribution of patients according to age and occurrence of hypothyroidism 
was tabulated 
Table-5.14 
Distribution of patients according to age and hypothyroidism. 
Age Normal  Hypothyroid  Total  
<40 2[50%] 2[50%] 4 
41-60 22[88%] 3[12%] 25 
>60 years 8[100%] 0 8 
Total  32 5 37 
 
Out of these 5 patients, who developed hypothyroidism, 2 patients were less than 40 years of 
age, and 3 were between 41 and 60. None of the patients above 60 years of age developed 
hypothyroidism in the present cohort. 
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The occurrence of hypothyroidism was more seen in the female subgroup. 
Table-5.15: Distribution of hypothyroidism according to sex 
 Total  Normal  hypothyroid P value 
Male  32 30[93.75] 2[40%] .0117 
Female  5 2[06.25%] 3[60%] 
Total  37 32 5  
 
 
There were 3 female patients who had developed hypothyroidism compared to 2 males, though 
the number of males was more in the study sample. The test for significance by Fishers exact T 
test was significant. However, as the absolute number of patients developing hypothyroidism is 
small the chance of a false positive association cannot be ruled out. 
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Fig-5.10:Distribution of incidence of hypothyroidism according to sex 
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Place of residence- 
As per the place of residence, only one patient [20%] who had developed hypothyroidism 
was a resident of Himalayan region.  
Table-5.16 
Distribution of patients according to occurrence of hypothyroidism and place of 
residence. 
 Hypothyroid  Normal  Total  
Himalayan 1[25%] 3[75%] 4 
Costal  4[12.12%] 29[87.78%] 33 
Total  5 32 37 
 
The incidence did not show any statistical significance. [p=.4555 by 2 tailed Fisher’s T test. 
Diabetes mellitus- 
There were no patients in the hypothyroid group who had DM. 
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Hypertension: 
Out of these 5 patients, 2 were known hypertensive.   
Table-5.17 
Distribution of patients with occurrence of hypothyroidism and hypertension. 
 Hypothyroid  Normal  Total  
Hypertension 2[33.33%] 4[66.66%] 6 
Normotensive  3[9.68%] 28[90.32%] 31 
Total  5 32 37 
 
The incidence did not show any statistical significance. [p=.1771 by 2 tailed 
Fisher’s T test] 
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Smoking- 
As per the habit of smoking there were 3 patients who had developed hypothyroidism.  
Table-5.18 
Distribution of patients with occurrence of hypothyroidism and smoking. 
 Hypothyroid  Normal  Total  
Smoker  2[11.11%] 16[88.89%] 18 
Non smoker  3[15.79%] 16[84.21%] 19 
Total  5 32 37 
 
The incidence did not show any statistical significance. [p=1 by 2 tailed Fisher’s T test. 
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Table-5.19: Distribution of patients according to treatment and development of 
hypothyroidism 
 Total  Normal  hypothyroid significance 
Radical radiotherapy 14 13 1[7.14%] X2 test 
value 
6.432, 
df=3, 
P=.091 
Not 
significant 
Radical chemo 
radiotherapy 
19 16 3[15.79%] 
Post-operative 
radiotherapy 
1 0 1[100%] 
Post-operative radio 
chemotherapy 
3 3 0[0%] 
Total 37 32 5 
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Table-5.20: Distribution of incidence of hypothyroidism with respect to total 
dose and fractionation received 
Schedule Total dose Normal Hypothyroid Total 
200 cGy x 33 
fractions 
6600 23 5[17.86%] 28 
225 cGy x 28 
fractions 
6300 4 0 4 
Simultaneous 
boost 
techniques 
Equivalent 
>66 Gy 
5 0 5 
Total - 32 5[13.51%] 37 
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Table-5.21: distribution of hypothyroidism according to the site and stage of the 
disease. 
 I II III IV a Total 
normal hypo normal hypo normal hypo normal hypo normal hypo 
Nasopharynx 0 0 0 0 0 0 1  1 0 
Oral cavity 1 0 0 0 `1 1 4 1 6 2 
Oropharynx  0 0 0 0 1 0 3 0 4 0 
Larynx  4 0 5 2 4 0 2 0 15 2 
Hypopharynx 1 0 0 0 0 0 5 1 6 1 
Total 6 0 5  6  15  32 5 
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Table-5.22 
Distribution of hypothyroidism according to site, stage and treatment modality 
A) Oral cavity 
Oral 
cavity 
Radiotherapy  chemo 
radiotherapy 
Post op 
radiotherapy 
Post op chemo 
radiotherapy 
total 
 Normal  Hypo  Normal  Hypo  Normal  Hypo  Normal  Hypo   
Stage 
I 
0 0 0 0 0 0 1 0 1 
Stage 
III 
0 0 0 0 0 1[50%] 1 0 2 
Stage 
IV 
1 0 2 1[20%] 0 0 1 0 5 
Total  1 0 2 1 0 1 3 0 8 
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B) Oropharynx:- 
Oropharyn
x 
Radiotherapy  chemo 
radiotherapy 
Post op 
radiotherapy 
Post op 
chemo 
radiotherapy 
tota
l 
 Norma
l 
Hyp
o  
Norma
l  
Hyp
o  
Norma
l  
Hyp
o  
Norma
l  
Hyp
o  
 
Stage III 0 0 1 0 0 0 0 0 1 
Stage IV 0 0 3 0 0 0 0 0 2 
Total  0 0 4 0 0 0 0 0 4 
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C) Larynx:- 
larynx Radiotherapy  chemo radiotherapy Post op 
radiotherapy 
total 
 Normal  Hypo  Normal  Hypo  Normal  Hypo   
Stage I 4 0 0 0 0 0 4 
Stage II 5 0 0 2 0 0 7 
Stage 
III 
0 0 4 0 0 0 4 
Stage 
IV 
0 0 1 0 1 0 2 
Total  9 0 5 0 1 0 17 
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D) Hypopharynx; 
Hypopharynx Radiotherapy  chemo radiotherapy total 
 Normal  Hypo  Normal  Hypo   
Stage I 0 0 1 0 1 
Stage IV 2 0 3 1 6 
Total  2 0 4 1 7 
 
E) Nasopharynx:- 
Nasopharyn
x 
Radiotherapy  chemo 
radiotherapy 
Post op 
radiotherapy 
Post op 
chemo 
radiotherapy 
tota
l 
 Norma
l 
Hyp
o  
Norma
l  
Hyp
o  
Norma
l  
Hyp
o  
Norma
l  
Hyp
o  
 
Stage IV 0 0 1 0 0 0 0 0 1 
Total  0 0 0 0 0 0 0 0 1 
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Distribution of the measured dose of radiation received to the thyroid gland region for all 
evaluable patients was found to be as follows- 
Table-5.23:distribution of surface dose to thyroid region for all patients 
 Minimum  Maximum  Range  Mean  Std 
deviation 
Dose in 
cGY 
2773.9 6803.81 4029.9 4931.60 1091.53 
                                                        
The distribution of measured dose for the patients who developed hypothyroidism was as 
follows:- 
Table-5.24:distribution of surface dose to thyroid region for all patients 
 
 Minimum  Maximum  Range  Mean  Std 
deviation 
Dose in 
cGY 
4614.05 6369.15 1755.10 5510.48 693.257 
 
  
79 | P a g e  
 
All those who had developed hypothyroidism had received more than 45 Gy as measured by 
TLD to the thyroid region. Out of them 4 had received more than 50 Gy.   
 
However, there were patients in the group, who had received higher doses to the same region, 
[>50 Gy] but had not developed hypothyroidism till date. The dose measurement was done at the 
surface level and was based on classical surface anatomy. However, in individual patients, the 
location of the thyroid gland might have differed significantly, and that the dose received to the 
thyroid would have varied based on the depth of the thyroid gland, which the surface dose did 
not take into consideration. Thus, the surface based dosimetry is not an alternative to image 
based and volume based determination of dose received to thyroid.  
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Table-5.25 -: Data of patients with iatrogenic hypothyroidism post radiotherapy 
ID  1 3 17 26 50 
Sex  M F F F M 
Age   60 32 40 55 56 
Area   ASSAM WB WB WB WB 
Diagnosis   LARYNX ORAL 
CAVITY 
ORAL 
CAVITY 
LARYNX HYPO 
PAHARYNX 
Stage   II III IVa II III 
DM  NIL NIL NIL NIL NIL 
HTN  YES YES NO NO NO 
Habits   SMOKER NIL BEETLE  
NUT 
NIL SMOKER 
Treatment   CHEMO-
RT 
POST 
OP RT 
CHEMO-
RT 
RT CHEMO-RT 
Dose  
& fraction 
 66 Gy  
33# 
66 Gy  
33# 
66 Gy  
33# 
66 Gy  
33# 
66 Gy  
33# 
Surface 
dose to 
thyroid 
region 
 5946.444 
 
6369.154 
 
5548.191 
 
5074.554 
 
4614.053 
 
Baseline 
[pre RT] 
TSH 1.79 3.02 3.38 3.16 4.20 
T4 8.60 12.30 9.90 7.60 7.80 
FTC 1.10 1.02 0.93 0.81 1.07 
FACT-
T 114 86 96 97 92 
1
st
 follow 
up 
TSH 0.63 9.75 8.75 2.67 12.89 
T4 8.60 7.70 7.90 8.70 6.00 
FTC 1.10 0.76 0.85 0.93 0.87 
FACT-
T 
108 99.00 96 102.00 93 
2
nd
 follow 
up 
TSH 17.12   32.65  
T4 6.10   6.20  
FTC 0.68   0.77  
FACT-
T 
99   98  
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Signs of hypothyroidism: 
The followings signs were asked for from the patients in form of thyroid questionnaire.  
The responses were divided into those obtained from patients at hypothyroid state and those in 
euthyroid state. There were a total of 58 post radiotherapy evaluable responses, at the time of 
detection of hypothyroidism. 
In first follow up,  
symptoms  Total (n) Euthyroid  Hypothyroid  p-value  
Fatigue  Present  3 3 0 1 
Absent  34 31 3 
Total  37 34 5 
Weight gain Present  8 5 3 .0072 
Absent  29 29 0 
Total  37 34 3 
Constipation  Present  3 1 1 .1577 
Absent  34 33 2 
Total  37 34 3 
Dry skin Present  1 0 1 .081 
Absent  36 34 2 
Total  37 34 3 
Cold 
intolerance 
Present  2 0 2 .0045 
Absent  35 34 1 
Total  37 34 3 
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Appetite  Present  8 7 1 .14 
Absent  29 27 2 
Total  37 34 3 
 
Fatigue, weight gain, dry skin, and cold intolerance were found to be significantly associated 
with incidence of hypothyroidism. Only one patient in the euthyroid group elicited a positive 
response of temper fluctuation, [patient had same response at base line] and one complained of 
joint pain. The last patient was known to be suffering from OA for the past 12 years and was on 
treatment. These tend continued in the cumulative data from the first and second follow up. 
symptoms  Total (n) Euthyroid  Hypothyroid  p-value  
Fatigue  Present  9 5 1 .4390 
Absent  48 47 4 
Total  57 52 5 
Weight gain Present  9 6 3 .0241 
Absent  48 46 2 
Total  57 52 5 
Constipation  Present  3 1 2 .018 
Absent  54 51 3 
Total  57 52 5 
Dry skin Present  3 0 2 .0063 
Absent  54 52 3 
Total  57 52 5 
Cold Present  3 0 3 .0003 
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intolerance Absent  54 52 2 
Total  57 52 5 
Appetite  Present  11 8 2 .2077 
Absent  46 44 3 
Total  57 52 5 
 
Fatigue, loss of appetite was present across the groups in both follow ups and was not 
significantly associated with the development of hypothyroidism in the post radiotherapy head 
and neck patients. 
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QUALITY OF LIFE ANALYSIS 
The quality of life was estimated by FACT score. The data so collected was analyzed and found 
that the total FACT scores had a significant improvement from the base line when tested with 
Wilkinson signed rank test.  
But the FACT score for those with hypothyroidism did not show any difference from baseline 
value, when compared to that at the point of developing of hypothyroidism. [p=.068] 
This suggests that the improvement in quality of life, post radiotherapy, was not significant when 
the patient develops hypothyroidism. 
 
 Comparing 
values 
Test used Null 
hypothesis 
P value Result  
1. All 
patients  
Total [baseline 
Vs. first follow 
up] 
Wilcoxin 
signed rank 
Test 
Median of 
differences 
between 
two groups 
are not 
significant 
.000 Reject null 
hypothesis 
2. All 
patients 
Total [baseline 
and last 
available] 
Wilcoxin 
signed rank 
Test 
Median of 
differences 
between 
two groups 
are not 
significant 
0.000 Reject null 
hypothesis 
3. New 
onset 
hypothy
roid 
patients  
Total [baseline 
and at time of 
detection of 
hypothyroidism] 
Wilcoxin 
signed rank 
Test 
Median of 
differences 
between 
two groups 
are not 
significant 
0.68 Retain null 
hypothesis 
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Hypothyroidism is found to be one of the long term side effects in patient undergoing 
radiotherapy for head and malignancies. It affects the quality of life but can be treated with 
thyroxine supplementation once detected. Treatment with thyroxine supplementation prevents 
complications of hypothyroidism. 
In the present study, the incidence of baseline hypothyroidism among the screened 
individuals was about 11%. This is similar to that reported by Shantha et al i.e. 8.8%.(29) 
During the study, 5 patients [13.51%] developed hypothyroidism during follow up. Out 
of these five patients who had developed hypothyroidism, 2 were below 40 years of age, and 3 
were between 41-60 years of age. There were no patients above 60 years of age. However, this 
was not of any statistical significance. A similar trend is seen in the findings on the Indian 
population by Aich et al in which the development of hypothyroidism was not related to age. (3)        
. 
Out of the 5 who had developed hypothyroidism 3 were female and 2 were male. The 
difference was statistically significant [p=.0117]. Alkan et al in his study also found female 
predominance but in an Indian study by Aich et al there was not association with sex.(30) 
Among the patients who had developed hypothyroidism, 3[60%] had received concurrent 
chemotherapy with Cisplatin [40 mg/m2] and the remaining 2 had only radical radiotherapy.  
This finding was not statistically significant. [P value of 1 by two tailed Fischer’s test]. In a study 
done by Aich et al there was no association between occurrence of hypothyroidism and 
concurrent chemotherapy with radiotherapy. (3) 
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In our study there was no significant relation of occurrence of hypothyroidism to the site 
of the disease, or stage of the disease. There was also no significant difference with respect to 
surgery, associated DM and hypertension.   
There seems to be a correlation between baseline TSH and development of 
hypothyroidism with 4 of the 5 patients (75%) who developed hypothyroidism on follow up post 
radiotherapy had a baseline TSH level more than 3.  On the other hand among the remaining 32 
patients who had normal thyroid function during follow up only 2 had baseline TSH levels more 
than 3.    
The measured surface dose to the thyroid region was not significantly associated with, the 
incidence of hypothyroidism. This is probably because the thyroid gland itself may vary in 
position and depth from patient to patient and therefore the surface dose based on surface 
marking of the thyroid may not be representative of the dose received to the thyroid gland. 
Alterio et al has also reported that point dose does not correlate with the incidence of 
hypothyroidism.  (33) 
Among the 5 patients who developed hypothyroidism following radiotherapy in our study 
3 [8.1%] occurred at first follow up [6 weeks post completion of radiotherapy] and 2 at second 
follow up [19 weeks post completion of radiotherapy]. This is much higher and earlier than that 
documented by Aich et al which were 0.57% at 6 weeks and 3.6% at 6 months. Ref However 
there is data from far eastern population reported by Nishiyama et al  which was similar to ours 
with significant rise in TSH at 4.5 months following completion of radiotherapy. (45)  
Though the incidence did not vary significantly from that of the western population as 
reported by Alkan et al what varied is the early onset of hypothyroidism in present group. ,(3)  
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Most of the western literature had stressed on the development of hypothyroidism as a late 
complication of the treatment and therefore recommended evaluation at a later stage after 
completion of treatment. This study shows that the Indian population is different from the 
western population in terms of early onset of hypothyroidism. The reason of such early onset 
may be due to genetic or environmental factors and needs to be explored. 
 The clinical symptoms generally associated with hypothyroidism [like fatigue, 
constipation, loss of appetite] are commonly present in most head and neck patients especially at 
the end of radiotherapy . In this study one  of the hypothyroid patients complained of fatigue and 
3 out of 5 patients were found to have weight gain. The occurrence of cold intolerance, 
[P=0.0045] in the first follow up and weight gain among the patients who developed 
hypothyroidism compared to the remaining euthyroid patients was found to be statistically 
significant[P=0.0072]. These symptoms were elicited only on asking as patients never took 
weight gain or cold intolerance as significant symptoms to be reported. Other symptoms like 
temper fluctuation, joint pain was not found in the present cohort. Occurrence of constipation, 
loss of appetite among those who developed hypothyroidism and the euthyroid patients, was not 
found to be statistically significant. 
The cumulative data at second follow up continued to show similar findings except for 
constipation and dry skin which now was of statistical significance.  
Evaluation of the quality of life score showed improvement in the median scores of patients who 
did not develop hypothyroidism following radiotherapy. There was neither improvement nor 
worsening in the patients who developed hypothyroidism, denoting a relatively poorer quality of 
life in these patients.  
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Limitations of the study:- 
 
The present analysis of the study is limited by the fact that all patients who have been 
recruited have still not reached the 6 weeks follow up period and are therefore not evaluable.  
 Longer follow up data is required to make significant observations about incidence and 
the impact of hypothyroidism in Indian population in comparison with those reported in 
literature. 
Inclusion of less number of patients undergoing conformal radiotherapy and less number 
of post op patients in the study. 
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Based on the present data it can be concluded that 
1. Hypothyroidism at baseline evaluation was 11% and the incidence of 
secondary hypothyroidism post radiotherapy was 13.51%  --  
2. Surface dose measurements as described in the earlier literature did not 
correlate with clinical outcome and should be looked into in the light of 
3D organ imaging and dose volume relationships in the era of modern 
radiotherapy. 
3. The significant clinical symptoms of secondary hypothyroidism are cold 
intolerance and weight gain seen as early as six weeks.  
4. Iatrogenic hypothyroidism occurred over a variable point of time during 
the follow up  period as early as 6 weeks and at 19 weeks of completion of 
radiotherapy. 
5. Females appeared to be more prone to develop post radiotherapy 
hypothyroidism. 
6. Those patients with TSH levels more than 3 m IU/ml at base line were 
found  to be  more prone to develop secondary hypothyroidism. 
7.  Hypothyrodism is a significant comorbid association at presentation 
which can   worsen with radiotherapy and early institution of treatment 
results in  improvement of quality of life. In view of this, a baseline and 
follow up TSH as routine should be incorporated in the management 
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schedule. This simple biochemical screening is a cost effective strategy to 
improve the quality of life in head and neck cancer. 
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1. Follow up of the present study to the planned duration of 
follow up 
2. Further study based on volumetric data for determination of 
dose volume relationship with incidence of hypothyroidism. 
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Serial no-______  
Date-__/__/____ 
A prospective study to determine the occurrence of hypothyroidism following treatment with radiation 
therapy in patients of head and neck carcinomas and factors influencing this 
Patient serial no in study-_________ 
Name- 
Hospital no-________________________________RT NO- ____/____/RT II 
Address-______________________________________ 
                  _____________________________________ 
State-_________________ PIN-____________________ 
Home Ph-_____________________ Mobile-____________________________ 
Local Ph No______________________________ 
DOB/Age (in yrs)-_____/____/________       (_________) 
Sex- M/F 
Diagnosis-_________________________________ 
Staging (TNM, stage format) - T___N____M____ stage _____ 
Any prior cancer directed treatment-Yes/No 
Any prior history of other malignancy- Yes/No 
Any prior history of radiation therapy for benign or malignant disorders- Yes/No 
Any history of thyroid disorders- Yes/No 
Any co-morbid conditions- 
DM-           /HTN-         /BA- 
Others 
Audio logical status- 
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Eligibility check list:- 
1. Age- adult- Yes/No 
2. Site-  
a. Hypo pharynx 
b. Larynx 
c. Oral cavity 
d. Nasal cavity without ICE 
e. NPX without ICE 
f. CUP 
g. None 
3. P.S.- 0/1/2/None 
4. Radiation field extends to neck- Yes/No 
5. Intention to treat- >50 Gy Yes/ No 
6. History of RT to neck- Yes/ No 
7. currently on thyroid supplements-Yes/NO 
8. Intracranial extension present-Yes/No 
Eligible for screening- Yes/No 
Pre treatment  
TSH- 
T4 
FTC 
Subject status- Included/ Excluded/ Screening failure 
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Treatment details- 
Radiotherapy- 
Type- 
Dose- 
Dose to thyroid (point) 
Volume of thyroid irradiated-(as calculated from TPS) 
Pre-RT surgery- Yes/ No 
If yes type- 
MRND- Yes-(unilateral/ Bilateral)/ No 
Neo- adjuvant chemotherapy- yes/no 
No of cycles- 
Drug and dose used- 
Concurrent chemotherapy-Yes/No 
Drug and dose used 
No of cycles- 
Adverse events during RT (if any)- 
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Demographic  and treatment details of the evaluable patients 
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FACT SCORE DATA of all recruited patients  
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Thyroid questionnaire data for all recruited patients 
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